Advice

in the absence of a submission from the holder of the marketing authorisation:

belzutifan (Welireg®) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) / programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Download detailed advice298KB (PDF)

Download

Medicine details

Medicine name:
belzutifan (Welireg®)
SMC ID:
SMC2864
Indication:

Treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) / programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Pharmaceutical company
Merck Sharp & Dohme Ltd
Submission type
Non submission
Date advice published
08 September 2025